KMT2A and colorectal cancer: For example, a genome-wide loss-of-function screen examining the β-catenin signalling pathway identified KMT2A as a potential target and in vitro validation confirmed that two KMT2A-menin suppress β-catenin–active colorectal cancer cells [75].